{"id":"https://openalex.org/W4367296164","doi":"https://doi.org/10.1212/wnl.0000000000202777","title":"Safety and efficacy of Cladribine in real life sitting, Kuwait Experience (P8-3.014)","display_name":"Safety and efficacy of Cladribine in real life sitting, Kuwait Experience (P8-3.014)","publication_year":2023,"publication_date":"2023-04-25","ids":{"openalex":"https://openalex.org/W4367296164","doi":"https://doi.org/10.1212/wnl.0000000000202777"},"language":"en","primary_location":{"id":"doi:10.1212/wnl.0000000000202777","doi":"https://doi.org/10.1212/wnl.0000000000202777","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.0000000000202777","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5025338838","display_name":"Malak AlMojel","orcid":"https://orcid.org/0000-0001-7736-3270","observed_orcids":["https://orcid.org/0000-0001-7736-3270"]},"institutions":[{"id":"https://openalex.org/I36721946","display_name":"Kuwait University","ror":"https://ror.org/021e5j056","country_code":"KW","type":"education","lineage":["https://openalex.org/I36721946"]}],"countries":["KW"],"is_corresponding":false,"raw_author_name":"Malak AlMojel","raw_affiliation_strings":["Department of Medicine, Faculty of Medicine, Kuwait University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Faculty of Medicine, Kuwait University","institution_ids":["https://openalex.org/I36721946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015301748","display_name":"Jasem Al-Hashel","orcid":"https://orcid.org/0000-0001-6371-7381","observed_orcids":["https://orcid.org/0000-0001-6371-7381"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jasem Al-Hashel","raw_affiliation_strings":["IBN Sina Hospital, AlSabah Medical Area, Neurology Department"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"IBN Sina Hospital, AlSabah Medical Area, Neurology Department","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049456235","display_name":"Raed Alroughani","orcid":"https://orcid.org/0000-0001-5436-5804","observed_orcids":["https://orcid.org/0000-0001-5436-5804","https://orcid.org/0000-0002-7111-0480"]},"institutions":[{"id":"https://openalex.org/I2803040547","display_name":"Amiri Hospital","ror":"https://ror.org/04y2hdd14","country_code":"KW","type":"healthcare","lineage":["https://openalex.org/I2803040547"]}],"countries":["KW"],"is_corresponding":false,"raw_author_name":"Raed Alroughani","raw_affiliation_strings":["Consultant of Neurology, Division of Neurology, Amiri Hospital"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Consultant of Neurology, Division of Neurology, Amiri Hospital","institution_ids":["https://openalex.org/I2803040547"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5000026859","display_name":"Samar Farouk Ahmed","orcid":"https://orcid.org/0000-0002-9026-9219","observed_orcids":["https://orcid.org/0000-0002-9026-9219"]},"institutions":[{"id":"https://openalex.org/I89466785","display_name":"Minia University","ror":"https://ror.org/02hcv4z63","country_code":"EG","type":"education","lineage":["https://openalex.org/I89466785"]}],"countries":["EG"],"is_corresponding":false,"raw_author_name":"Samar Ahmed","raw_affiliation_strings":["Professor of Neurology, Minia Univercity, Egypt"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Professor of Neurology, Minia Univercity, Egypt","institution_ids":["https://openalex.org/I89466785"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"100","issue":"17_supplement_2","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11827","display_name":"Polyomavirus and related diseases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cladribine","display_name":"cladribine","score":0.9760000109672546},{"id":"https://openalex.org/keywords/multiple-sclerosis","display_name":"multiple sclerosis","score":0.9919999837875366},{"id":"https://openalex.org/keywords/real-world-effectiveness","display_name":"real-world effectiveness","score":0.7570000290870667},{"id":"https://openalex.org/keywords/relapse-rate","display_name":"relapse rate","score":0.7390000224113464},{"id":"https://openalex.org/keywords/disability-progression","display_name":"disability progression","score":0.9520000219345093},{"id":"https://openalex.org/keywords/neda-3","display_name":"NEDA-3","score":0.6800000071525574},{"id":"https://openalex.org/keywords/gadolinium-enhancement","display_name":"gadolinium enhancement","score":0.6480000019073486},{"id":"https://openalex.org/keywords/t2-lesions","display_name":"T2 lesions","score":0.746999979019165},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.8059999942779541},{"id":"https://openalex.org/keywords/lymphopenia","display_name":"lymphopenia","score":0.9520000219345093},{"id":"https://openalex.org/keywords/liver-enzymes","display_name":"liver enzymes","score":0.6759999990463257},{"id":"https://openalex.org/keywords/early-treatment-initiation","display_name":"early treatment initiation","score":0.7730000019073486},{"id":"https://openalex.org/keywords/disease-modifying-therapy","display_name":"disease-modifying therapy","score":0.8550000190734863},{"id":"https://openalex.org/keywords/kuwaiti-patients","display_name":"Kuwaiti patients","score":0.5569999814033508},{"id":"https://openalex.org/keywords/treatment-efficacy-and-safety","display_name":"treatment efficacy and safety","score":0.574999988079071},{"id":"https://openalex.org/keywords/treatment-naive-patients","display_name":"treatment-naive patients","score":0.5619999766349792}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9032901525497437},{"id":"https://openalex.org/C2779200787","wikidata":"https://www.wikidata.org/wiki/Q414030","display_name":"Cladribine","level":2,"score":0.8618214726448059},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6179366707801819},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5653069615364075},{"id":"https://openalex.org/C23131810","wikidata":"https://www.wikidata.org/wiki/Q818574","display_name":"Observational study","level":2,"score":0.5611333250999451},{"id":"https://openalex.org/C2780640218","wikidata":"https://www.wikidata.org/wiki/Q8277","display_name":"Multiple sclerosis","level":2,"score":0.5071959495544434},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.5021755695343018},{"id":"https://openalex.org/C201903717","wikidata":"https://www.wikidata.org/wiki/Q1778788","display_name":"Cohort study","level":2,"score":0.44299203157424927},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3430096209049225},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1212/wnl.0000000000202777","doi":"https://doi.org/10.1212/wnl.0000000000202777","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.0000000000202777","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4362468383","https://openalex.org/W4383671822","https://openalex.org/W4363677407","https://openalex.org/W4366977972","https://openalex.org/W4385327353","https://openalex.org/W4362692406","https://openalex.org/W4405350202","https://openalex.org/W7205296501","https://openalex.org/W7162104985","https://openalex.org/W4362469295"],"abstract_inverted_index":{"Objective:":[0],"To":[1],"study":[2,38,237],"the":[3,6,122,276,305],"effectiveness":[4,229],"and":[5,58,76,138,148,219,230],"safety":[7,231],"of":[8,25,52,87,119,124,128,170,176,180,196,233,242,249,278,307],"Cladribine":[9,20,53,67,210],"treatment":[10,24],"in":[11,14,155,187,194,201,235,275,304],"MS":[12,40],"patients":[13,41,105,114,198,202],"a":[15,283,312],"real-world":[16],"clinical":[17,57,245],"setting.":[18],"Background:":[19],"was":[21,131,161,185,192],"approved":[22],"for":[23,280,291,309,315],"multiple":[26],"sclerosis":[27],"(MS).":[28],"Real-world":[29],"data":[30,241],"is":[31,251],"very":[32],"limited.":[33],"Design/Methods:":[34],"This":[35],"observational,":[36],"prospective":[37],"included":[39],"who":[42,203],"had":[43,140],"at":[44,79],"least":[45],"one":[46,63],"year":[47,64],"follow-up":[48],"after":[49],"second":[50],"course":[51],"treatment.":[54,112,120],"Baseline":[55],"patient":[56],"radiological":[59,74],"characteristics":[60],"recorded":[61],"within":[62],"prior":[65,205],"to":[66,110,158,261,267,326],"initiation.":[68,211],"The":[69,228],"relapse":[70,132],"rate,":[71],"disability":[72],"measures,":[73],"activity":[75,182],"adverse":[77],"events":[78],"last":[80],"visit":[81],"were":[82,92,108,225,238],"assessed.":[83],"Results:":[84],"A":[85],"total":[86],"seventy-two":[88],"patients,":[89],"59":[90],"(81.9%)":[91],"females,":[93],"mean":[94,100],"age":[95],"36.32":[96],"\u00b110.06":[97],"years":[98],"old,":[99],"disease":[101,181,206],"duration":[102],"7.21\u00b16.19.":[103],"Most":[104,169],"(n=32;":[106],"44.4%)":[107],"na\u00efve":[109],"any":[111],"Forty":[113],"(55.6%)":[115],"completed":[116],"two":[117],"courses":[118],"At":[121],"end":[123],"observational":[125],"period,":[126],"most":[127],"our":[129],"cohort":[130,171],"free":[133],"(85%":[134],"versus":[135,145,152,166,199],"25%;":[136],"P<0.001)":[137,154],"few":[139],"new":[141],"T2":[142],"lesions":[143],"(7.5%":[144],"70.8%;":[146],"P<0.001":[147],"gadolinium":[149],"enhancement":[150],"5%":[151],"66.7%;":[153],"MRI":[156],"compared":[157],"baseline.":[159],"ARR":[160],"significantly":[162],"reduced":[163],"0.15":[164],"\u00b10.36":[165],"0.85\u00b10.53;":[167],"P<0.01).":[168],"90%":[172],"has":[173,259,265,271,300,324],"no":[174],"progression":[175],"disability.":[177],"No":[178],"evidence":[179],"3":[183,244],"(NEDA-3)":[184],"achieved":[186,193],"30":[188],"(75%)":[189],"patients.":[190],"It":[191],"87.5%":[195],"naive":[197],"66.7%":[200],"received":[204,272,301],"modification":[207],"drugs":[208],"before":[209],"Infections":[212],"6":[213],"(n=6;":[214],"8.4%)":[215],"lymphocytopenia":[216],"(n=3;":[217],"4.2%),":[218],"elevated":[220],"liver":[221],"enzymes":[222],"(n=1;":[223],"1.4%)":[224],"reported.":[226],"Conclusions:":[227],"profile":[232],"cladribine":[234,250],"this":[236],"consistent":[239],"with":[240,253],"phase":[243],"trials.":[246],"Early":[247],"initiation":[248],"associated":[252],"favorable":[254],"outcome.":[255],"Disclosure:":[256],"Dr.":[257,263,269,298,322],"AlMojel":[258],"nothing":[260,266,325],"disclose.":[262,268,327],"Al-Hashel":[264],"Alroughani":[270,299],"personal":[273,302],"compensation":[274,303],"range":[277,306],"$5,000-$9,999":[279,308],"serving":[281,310],"on":[282,311],"Scientific":[284],"Advisory":[285],"or":[286],"Data":[287],"Safety":[288],"Monitoring":[289],"board":[290],"Biogen,":[292,317],"Bayer,":[293,316],"Novartis,":[294,318],"Merck,":[295,319],"Roche,":[296,320],"Sanofi.":[297,321],"Speakers":[313],"Bureau":[314],"Ahmed":[323]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-04-29T00:00:00"}